Shinzawa H, Yoshida Y, Masamune O, Toyota T, Takahashi T, Kasukawa R, Sudo T, Ishikawa K, Komatsu M, Ishii M, Takagi T, Hisamichi S, Sato S, Ichida H
Second Department of Internal Medicine, Yamagata University School of Medicine, Japan.
Dig Dis Sci. 2000 Mar;45(3):575-80. doi: 10.1023/a:1005409627192.
A controlled trial was conducted to compare the efficacy of interferon (IFN) between two groups of patients with type C liver. Thirty-five patients were randomly assigned to group A (17 patients) or group B (18 patients). The former received 3 megaunits (MU) of human lymphoblastoid IFN six days per week for two weeks, followed by three days per week for 50 weeks; the latter group received 6 MU six days per week for two weeks followed by three days per week for 24 weeks. The percentages of biological sustained responders (B-SR) and virological sustained responders (V-SR) were 29.4 and 23.5%, respectively, in group B, and 17.6% for both in group A. The therapeutic effects were not different between two groups. HCV genotype 2 accounted for significantly higher percentage of B-SR and V-SR (both 57.1%, respectively). These findings indicate that IFN is effective in type C cirrhosis with genotype 2.
进行了一项对照试验，比较两组丙型肝炎患者使用干扰素（IFN）的疗效。35例患者被随机分为A组（17例）或B组（18例）。前者每周6天接受3百万单位（MU）人淋巴母细胞干扰素，共两周，之后每周3天，持续50周；后者每周6天接受6 MU，共两周，之后每周3天，持续24周。B组的生物学持续应答者（B-SR）和病毒学持续应答者（V-SR）的百分比分别为29.4%和23.5%，A组两者均为17.6%。两组之间的治疗效果无差异。HCV基因型2在B-SR和V-SR中所占百分比显著更高（分别均为57.1%）。这些发现表明，IFN对基因型2的丙型肝炎肝硬化有效。
